Ruben Mayer, MD
Internal Medicine · Columbia, SCNPI 1891755039
Payments from drug & device makers
Across 194 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$514
- Novo Nordisk$438
- AstraZeneca$431
- Pfizer$290
- Dexcom, Inc.$274
- AbbVie$234
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,402100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 34 | $514 |
| Novo Nordisk | 26 | $438 |
| AstraZeneca | 24 | $431 |
| Pfizer | 16 | $290 |
| Dexcom, Inc. | 8 | $274 |
| AbbVie | 14 | $234 |
| Novartis | 10 | $198 |
| Amgen | 11 | $174 |
| Boehringer Ingelheim | 8 | $131 |
| Abbott | 4 | $88 |
| Exact Sciences | 5 | $78 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $75 |
| Astellas Pharma US Inc | 3 | $50 |
| Bayer | 3 | $49 |
| GSK | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Zimmer Biomet | 1 | $38 |
| Dynavax Technologies Corporation | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $27 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Gilead | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Antares Pharma, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $14 |
| Merck | 1 | $14 |
| Shield Therapeutics Inc | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Inari Medical, Inc. | 1 | $13 |
| Halozyme Inc | 1 | $13 |
| Edwards Lifesciences | 1 | $13 |
How this compares
$3,402 in reported general payments places this provider in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $159,347 |
| FarxigaDapagliflozin Propanediol | 133 | $122,657 |
| EliquisApixaban | 95 | $73,778 |
| OzempicSemaglutide | 39 | $56,904 |
| RybelsusSemaglutide | 35 | $54,041 |
| XareltoRivaroxaban | 46 | $43,213 |
| MounjaroTirzepatide | 24 | $35,131 |
| TrintellixVortioxetine Hydrobromide | 29 | $27,631 |
| JanuviaSitagliptin Phosphate | 13 | $19,015 |
| Rosuvastatin Calcium | 652 | $17,161 |
| MyrbetriqMirabegron | 25 | $14,154 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $13,890 |
| Repatha SureclickEvolocumab | 15 | $11,994 |
| Levothyroxine Sodium | 590 | $9,862 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $9,040 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $131 | $173,237133 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $431 | $138,227174 claims |
| Novo NordiskOzempic, Rybelsus | $438 | $110,94574 claims |
| PfizerEliquis | $290 | $73,77895 claims |
| Johnson & JohnsonXarelto | $14 | $43,21346 claims |
| Lilly USA, LLCMounjaro | $514 | $35,13124 claims |
| MerckJanuvia, Janumet | $14 | $28,04928 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $20 | $27,63129 claims |
| Astellas Pharma US IncMyrbetriq | $50 | $14,15425 claims |
| GSKBreo Ellipta | $45 | $4,72614 claims |
| AbbVieSynthroid | $234 | $3,82458 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Columbia
- Carl MitchellColumbia$564K
- Ronald CassadaColumbia$100K
- Meer FakhryColumbia$22K
- Charles ButlerColumbia$19K
- Laura LabooneColumbia$16K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.